Jones Financial Companies’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.72M Buy
22,474
+2,895
+15% +$568K ﹤0.01% 1219
2026
Q1
$3.83M Buy
19,579
+14,575
+291% +$2.83M ﹤0.01% 1182
2025
Q4
$868K Buy
5,004
+717
+17% +$131K ﹤0.01% 1290
2025
Q3
$810K Buy
4,287
+1,174
+38% +$208K ﹤0.01% 1207
2025
Q2
$554K Buy
3,113
+447
+17% +$77.6K ﹤0.01% 1241
2025
Q1
$446K Buy
2,666
+818
+44% +$134K ﹤0.01% 1180
2024
Q4
$279K Buy
1,848
+998
+117% +$155K ﹤0.01% 1203
2024
Q3
$132K Buy
850
+325
+62% +$48.5K ﹤0.01% 1301
2024
Q2
$71.9K Buy
525
+375
+250% +$51.4K ﹤0.01% 1143
2024
Q1
$20K Buy
+150
New +$19.5K ﹤0.01% 908
2022
Q3
Sell
-35
Closed -$5K 576
2022
Q2
$5K Hold
35
﹤0.01% 542
2022
Q1
$5K Sell
35
-267
-88% -$37.2K ﹤0.01% 575
2021
Q4
$52K Hold
302
﹤0.01% 360
2021
Q3
$44K Buy
302
+267
+763% +$39.1K ﹤0.01% 335
2021
Q2
$5K Hold
35
﹤0.01% 558
2021
Q1
$4K Buy
+35
New +$4.31K ﹤0.01% 644

Other funds holding DGX

Jones Financial Companies's DGX Position: Q2 2026 in Review

Jones Financial Companies increased its Quest Diagnostics (DGX) stake by 15% in Q2 2026, buying an estimated $568K and bringing the position to 22,474 shares worth $4.72M. The position accounts for ﹤0.01% of the portfolio, ranked #1219.

Jones Financial Companies first reported a position in DGX in Q1 2021 and has held it in 16 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Jones Financial Companies held 22,474 shares of Quest Diagnostics worth $4.72M as of Q2 2026.
  • Jones Financial Companies bought 2,895 Quest Diagnostics shares in Q2 2026, an estimated $568K.
  • Quest Diagnostics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #1219 holding.
  • Jones Financial Companies first reported a position in Quest Diagnostics in Q1 2021 and has held it in 16 quarters since.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.